Pralsetinib 100 mg Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 mg
Reference Brands: Gavreto (USA/EU)
Category: Oncology Cancer Care
Pralsetinib is a selective RET (rearranged during transfection) kinase inhibitor used to treat cancers that harbor RET gene fusions or mutations. It is administered orally and represents a targeted therapy for certain non-small cell lung cancers and thyroid cancers with RET alterations.
Pralsetinib — third party manufacturing & bulk supply
Pralsetinib 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Pralsetinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Pralsetinib →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Pralsetinib is used for the treatment of non-small cell lung cancer (NSCLC) and thyroid cancers that have a rearranged during transfection (RET) gene alteration. It works as a selective RET kinase inhibitor, blocking the activity of abnormal RET proteins that drive cancer cell growth.
Pralsetinib is made from the active ingredient pralsetinib, a small-molecule tyrosine kinase inhibitor specifically designed to target RET fusion–positive or RET-mutant cancers.
The trade name of Pralsetinib is Gavreto.
Pralsetinib (Gavreto) is developed and marketed by Blueprint Medicines in collaboration with Genentech (a member of the Roche Group).
The generic name is Pralsetinib.
The brand name is Gavreto.
Pralsetinib is manufactured in the United States and Switzerland by Blueprint Medicines and Roche facilities following international regulatory standards for oncology drugs.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
